Mikobakteriyel Enfeksiyonlarda Yeni İlaç Adayları
Referanslar
World Health Organization. Global tuberculosis report 2025. Geneva: WHO; 2025.
Hoelscher M, Barros-Aguirre D, Dara M, et al. Candidate anti-tuberculosis medicines and regimens under clinical evaluation. Clinical Microbiology and Infection. 2024;30:1131–1138. doi:10.1016/j.cmi.2024.06.016.
Dartois V, Dick T. Therapeutic developments for tuberculosis and Mycobacterium abscessus pulmonary disease. Nature Reviews Drug Discovery. 2024;23:381–403.
Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nature Reviews Microbiology. 2022;20:685–701. doi:10.1038/s41579-022-00731-y.
Lienhardt C, Brigden G, Castro JL, et al. Target regimen profiles for tuberculosis treatment. European Respiratory Journal. 2024;64(1):2302016. doi:10.1183/13993003.02016-2023.
Capela R, Moreira R, Lopes F. Target identification in anti-tuberculosis drug discovery. Molecules. 2023;28:4653. doi:10.3390/molecules28124653.
Li S, Poulton NC, Chang JS, et al. CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis. Nature Microbiology. 2022;7:766–779. doi:10.1038/s41564-022-01130-y.
Sarathy JP, Ragunathan P, Shin J, et al. TBAJ-876 displays bedaquiline-like mycobactericidal potency without retaining the parental drug’s uncoupler activity. Antimicrobial Agents and Chemotherapy. 2020;64:e01540-19. doi:10.1128/AAC.01540-19.
Mudde SE, Ammerman NC, ten Kate MT, et al. Relative contributions of the novel diarylquinoline TBAJ-876 and its active metabolite to the bactericidal activity in a murine model of tuberculosis. The Journal of Infectious Diseases. 2024;230(6):e1366–e1374. doi:10.1093/infdis/jiae332.
Olugbosi M, Beumont M, Lombard L, et al. Protocol for a phase 2, partially blinded, randomized trial assessing the safety and efficacy of sorfequiline or bedaquiline, in combination with pretomanid and linezolid in adult participants with newly diagnosed, drug-sensitive, smear-positive pulmonary tuberculosis (NC-009). Trials. 2026;27:102. doi:10.1186/s13063-025-09413-5.
Xu J, Converse PJ, Upton AM, et al. Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy. 2021;65:e02418-20. doi:10.1128/AAC.02418-20.
Nedelman J, Conradie A, Lombardi A, et al. Pharmacokinetics and safety of TBAJ-587, a novel antimycobacterial diarylquinoline, in healthy participants. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01930-25.
Makarov V, Manina G, Mikusova K, et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science. 2009;324:801–804. doi:10.1126/science.1171583.
Hariguchi N, Chen X, Hayashi Y, et al. OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DprE1 inhibitor. Antimicrobial Agents and Chemotherapy. 2020;64:e02020-19. doi:10.1128/AAC.02020-19.
Dawson R, Diacon AH, Variava E, et al. Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial. The Lancet Infectious Diseases. 2026. doi:10.1016/S1473-3099(26)00143-X.
Heinrich N, de Jager V, Dreisbach J, et al. Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial. The Lancet Microbe. 2025;6(2):100952. doi:10.1016/j.lanmic.2024.07.015.
Chen RH, Burke A, Cho JG, Alffenaar JW, Davies Forsman L. New oxazolidinones for tuberculosis: are novel treatments on the horizon? Pharmaceutics. 2024;16(6):818. doi:10.3390/pharmaceutics16060818.
Heinrich N, Manyama C, Koele SE, et al. Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial. The Lancet Infectious Diseases. 2025;25(11):1208–1218. doi:10.1016/S1473-3099(25)00213-0.
Minja LT, van der Feltz I, Manyama C, et al. Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial. The Lancet Infectious Diseases. 2025;25(11):1219–1229. doi:10.1016/S1473-3099(25)00289-0.
Lombardi A, Pappas F, Bruinenberg P, et al. Pharmacokinetics, tolerability, and safety of TBI-223, a novel oxazolidinone, in healthy participants. Antimicrobial Agents and Chemotherapy. 2025;69:e01542-24. doi:10.1128/aac.01542-24.
Janssen S, Upton C, de Jager VR, et al. Telacebec, a potent agent in the fight against tuberculosis: findings from a randomized phase 2 clinical trial and beyond. American Journal of Respiratory and Critical Care Medicine. 2025;211(8):1504–1512. doi:10.1164/rccm.202408-1632OC.
Diacon AH, Barry CE, Carlton A, et al. A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomised trial. Nature Medicine. 2024;30:896–904. doi:10.1038/s41591-024-02829-7.
Pieren M, Abáigar Gutiérrez-Solana A, Antonijoan Arbós RM, et al. First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug. Journal of Antimicrobial Chemotherapy. 2024;79(6):1353–1361. doi:10.1093/jac/dkae107.
Zhang B, Li J, Yang X, et al. Crystal structures of membrane transporter MmpL3, an anti-TB drug target. Cell. 2019;176:636–648.e13. doi:10.1016/j.cell.2019.01.003.
Moreira W, Ngan GJY, Low JL, et al. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria. mBio. 2015;6:e00253-15. doi:10.1128/mBio.00253-15.
Chapman TM, Bouloc N, Buxton RS, et al. Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis. Bioorganic & Medicinal Chemistry Letters. 2012;22(9):3349-3353.
Ballinger E, Mosior J, Hartman T, et al. Opposing reactions in coenzyme A metabolism sensitize Mycobacterium tuberculosis to enzyme inhibition. Science. 2019;363(6426):eaau8959. doi:10.1126/science.aau8959.
Ottavi S, Scarry SM, Mosior J, et al. In vitro and in vivo inhibition of the Mycobacterium tuberculosis phosphopantetheinyl transferase PptT by amidinoureas. Journal of Medicinal Chemistry. 2022;65(3):1996-2022. doi:10.1021/acs.jmedchem.1c01565.
Wang S, Wang K, Song K, et al. Structures of the Mycobacterium tuberculosis efflux pump EfpA reveal the mechanisms of transport and inhibition. Nature Communications. 2024;15:7710. doi:10.1038/s41467-024-51948-9.
Dooley KE, Hanna D, Mave V, Eisenach K, Savic RM. Advancing the development of new tuberculosis treatment regimens: the essential role of translational and clinical pharmacology and microbiology. PLOS Medicine. 2019;16(7):e1002842. doi:10.1371/journal.pmed.1002842.
ClinicalTrials.gov. Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary TB. NCT05971602. Available from: https://clinicaltrials.gov/study/NCT05971602. Accessed August 13, 2026.
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. European Respiratory Journal. 2020;56(1):2000535. doi:10.1183/13993003.00535-2020.
Ussery XT, Bhatt N, Critchley IA, et al. Randomized study of the efficacy, safety, and pharmacokinetics of SPR720 for the treatment of Mycobacterium avium complex pulmonary disease. Scientific Reports. 2026;16:10063. doi:10.1038/s41598-026-40505-7.
ClinicalTrials.gov. A study of epetraborole in patients with treatment-refractory Mycobacterium avium complex lung disease (EBO-301). Identifier: NCT05327803. Available from: https://clinicaltrials.gov/study/NCT05327803. Accessed August 13, 2026.
Phelps GA, Killam BY, Lee RE, et al. Development of second-generation aminomethyl spectinomycins that overcome native efflux in Mycobacterium abscessus. Proceedings of the National Academy of Sciences of the United States of America. 2024;121(2):e2314101120. doi:10.1073/pnas.2314101120.
Dartois V, Lan T, Ganapathy US, et al. Next-generation rifamycins for the treatment of mycobacterial infections. Proceedings of the National Academy of Sciences of the United States of America. 2025;122(18):e2423842122. doi:10.1073/pnas.2423842122.
Zheng L, Qi Q, He Z, et al. Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae and Mycobacterium fortuitum in vitro and in vivo. Infection and Drug Resistance. 2023;16:1985-1996. doi:10.2147/IDR.S400318.
Padmapriyadarsini C, Bhavani PK, Natrajan M, et al. Evaluation of metformin in combination with rifampicin-containing antituberculosis therapy in patients with new, smear-positive pulmonary tuberculosis: a randomized controlled trial. Clinical Infectious Diseases. 2022;75(3):425-434. doi:10.1093/cid/ciab964.
Ammerman NC, Nuermberger EL, Owen A, et al. Potential impact of long-acting products on the control of tuberculosis: preclinical advancements and translational tools in preventive treatment. Clinical Infectious Diseases. 2022;75(Suppl 4):S510–S516. doi:10.1093/cid/ciac672.
Dedrick RM, Guerrero-Bustamante CA, Garlena RA, et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nature Medicine. 2019;25(5):730-733. doi:10.1038/s41591-019-0437-z.
Dedrick RM, Smith BE, Cristinziano M, et al. Phage therapy of mycobacterium infections: compassionate use of phages in 20 patients with drug-resistant mycobacterial disease. Clinical Infectious Diseases. 2023;76(1):103-112. doi:10.1093/cid/ciac453.
Stokes JM, Yang K, Swanson K, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688-702.e13. doi:10.1016/j.cell.2020.01.021.
The CRyPTIC Consortium and the 100,000 Genomes Project. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. The New England Journal of Medicine. 2018;379(15):1403-1415. doi:10.1056/NEJMoa1800474.
O’Brien D, Muhi S, Ellis K, et al. An open-label multicenter phase 2 trial of telacebec for adults with Buruli ulcer: the TREAT-BU trial. Open Forum Infectious Diseases. 2026;13(Suppl 1):ofaf695.020. doi:10.1093/ofid/ofaf695.020.
TB Alliance. Phase 2 clinical trial results show potential to shorten TB treatment time. November 19, 2025. Available from: https://www.tballiance.org/phase-2-clinical-trial-results-show-potential-to-shorten-tb-treatment-time/. Accessed August 13, 2026.